Self-dissolving micropiles for the percutaneous absorption of recombinant human growth hormone in rats

Biological and Pharmaceutical Bulletin

Volumn 31, Issue 8, 2008, Pages 1631-1633

  Ito, Yukako ^a   Ohashi, Yoshinori ^a   Shiroyama, Keiji ^a   Sugioka, Nobuyuki ^a   Takada, Kanji ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Absorption; Micropile; Percutaneous administration; Rat; Recombinant human growth hormone

Indexed keywords

DEXTRAN; HUMAN GROWTH HORMONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; ENZYME LINKED IMMUNOSORBENT ASSAY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; SELF DISSOLVING MICROPILE; SKIN ABSORPTION; STATISTICAL ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; AREA UNDER CURVE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HALF-LIFE; HUMAN GROWTH HORMONE; INJECTIONS, INTRAVENOUS; MALE; NANOPARTICLES; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; SKIN ABSORPTION;

EID: 48849112201     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.31.1631     Document Type: Article

References (25)

1. Gelato M. C., Merriam G. R., Annu. Rev. Physiol., 48, 569-591 (1986).
2. Janssen Y. J., Hamdy N. A., Frolich M., Roelfsema F., J. Clin. Endocrinol. Metab., 83, 2143-2148 (1998).
3. Vance M. L., Mauras N., N. Engl. J. Med., 341, 1206-1216 (1999).
4. Janssen Y. J., Doornbos J., Roelfsema F., J. Clin. Endocrinol. Metab., 84, 279-284 (1999).
5. Dorr H. G., Zabransky S., Keller E., Otten B. J., Partsch C. J., Nyman L., Gillespie B. K., Lester N. R., Wilson A. M., Hyren C., van Kuijck M. A., Schuld P., Schoenfeld S. L., J. Pediatr. Endocrinol. Metab., 16, 383-392 (2003).
6. Silverstein J. H., Murray F. T., Malasanos T., Myers S., Johnson F. B., Frye K., Grossman M., Endocrine, 15, 15-17 (2001).
7. Cheng Y.-H., Dyer A. M., J-Gill I., Hinchcliffe M., Nankervis R., Smith A., Watts P., Eur. J. Pharm. Sci., 26, 9-15 (2005).
8. Moore J. A., Pletcher S. A., Ross M. J., Int. J. Pharm., 34, 35-43 (1986).
9. Li H., Song J.-W., Park J.-S., Han K., Int. J. Pharm., 258, 11-19 (2003).
10. Lam X. M., Duenas E. T., Cleland J. L., J. Pharm. Sci., 90, 1356-1365 (2001).
11. Kim H. K., Park T. G., Int. J. Pharm., 229, 107-116 (2001).
12. Barry B., Williams A., Adv. Drug Deliv. Rev., 56, 603-618 (2003).
13. Cevc G., Adv. Drug Deliv. Rev., 56, 675-711 (2004).
14. Preat V., Vanbever R., Adv. Drug Deliv. Rev., 56, 659-674 (2004).
15. Doukas A., Adv. Drug Deliv. Rev., 56, 559-579 (2004).
16. Mitragotri S., Kost J., Adv. Drug Deliv. Rev., 56, 589-601 (2004).
17. Ito Y., Hagiwara E., Saeki A., Sugioka N., Takada K., Eur. J. Pharm. Sci., 29, 82-88 (2006).
18. Ito Y., Yoshimitsu J., Shiroyama K., Sugioka N., Takada K., J. Drug Target., 14, 255-262 (2006).
19. Yoshikawa Y., Kato K., Sone H., Takada K., Jpn. J. Clin. Pharmacol., 29, 475-487 (1998).
20. Nagamine J., Nagata R., Seki H., Akimaru N., Ueki Y., Kumagai K., Taiji M., Noguchi H., J. Endocrinol., 171, 481-489 (2001).
21. "Martindale," 33rd ed., ed. by Sweetman S. C., Pharmaceutical Press, London, 2002, pp. 1286-1288.
22. Toogood A. A., Naas R. M., Pezzoli S. S., O'Neill P. A., Thorner M. O., Shalet S. M., J. Clin. Endocrinol. Metab., 82, 2215-2221 (1997).
23. Ito Y., Hagiwara E., Saeki A., Sugioka N., Takada K., Eur. J. Pharm. Sci., 29, 82-88 (2006).
24. Ito Y., Yoshimitsu J., Shiroyama K., Sugioka N., Takada K., J. Drug Target., 14, 255-261 (2006).
25. Ito Y., Murakami A., Maeda T., Sugioka N., Takada K., Int. J. Pharm., 349, 124-129 (2008).